Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that the Minister of Industry, under the Investment Canada Act, has approved the acquisition of Aspreva by Galenica Group (SWX: GALN) through a wholly-owned Canadian subsidiary at a price of US$26.00 per share in cash.

The transaction, which is being carried out by way of a statutory plan of arrangement under Section 288 of the British Columbia Business Corporations Act, was approved by Aspreva shareholders and optionholders at a special meeting held on December 17, 2007. In addition, the British Columbia Supreme Court issued a final order approving the plan of arrangement on December 18, 2007. Under the terms of the Combination Agreement entered into on October 17, 2007 all conditions to Galenica's obligation to complete the transaction will be deemed to have been satisfied or waived two business days after the date of this press release. Closing of the transaction is subject to the satisfaction or waiver of the remaining conditions for the benefit of Aspreva as specified in the Combination Agreement. The transaction is expected to close on January 3, 2008.

Further details regarding the terms of the transaction are set out in Aspreva's management information circular dated November 15, 2007, which was filed by Aspreva on the Canadian SEDAR website at www.sedar.com and on the United States Securities and Exchange Commission's website at www.sec.gov.

Financial and Legal Advisors
Lazard Frères & Co. LLP and Lehman Brothers Inc. have acted as financial advisors to Aspreva with respect to the plan of arrangement. Aspreva's legal advisors are Farris, Vaughan, Wills & Murphy LLP, McCarthy Tétrault LLP and Cooley Godward Kronish LLP.

About Galenica
Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks. The Galenica Group enjoys a leading position in all its areas of activity – pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing. A large part of Galenica's income is generated by international operations. For more information please visit www.galenica.com.

About Aspreva
Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Learn more about the company at www.aspreva.com.

For Further Information please contact:
Sage J. Baker
Vice President, IR & Corporate Communications
Aspreva Pharmaceuticals
+1 250-708-4270
sbaker@aspreva.com